Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.45 |
| ▸ | CCR2 | P41597 | 6/20 | 0.45 |
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 5/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295967 | 0.92 | EPHX2 (0.43) | EPHX2CCR2TACR1CCR5MCHR1 | |
| SCHEMBL297773 | 0.86 | TACR3 (0.45) | TACR1CCR5MCHR1TACR2 | |
| SCHEMBL296677 | 0.81 | TACR2 (0.50) | TACR1CCR5TACR2 | |
| SCHEMBL921770 | 0.80 | EPHX2 (0.44) | EPHX2P2RX7CCR2TACR1CCR5 | |
| SCHEMBL295981 | 0.80 | TACR2 (0.45) | TACR1CCR5MCHR1TACR2 | |
| SCHEMBL296621 | 0.79 | TACR3 (0.45) | TACR1CCR5MCHR1TACR2 | |
| SCHEMBL297799 | 0.79 | TACR3 (0.49) | EPHX2P2RX7TACR1TACR2DDR1 | |
| SCHEMBL296951 | 0.79 | TACR3 (0.47) | TACR1CCR5MCHR1TACR2 | |
| SCHEMBL295129 | 0.78 | SLC6A3 (0.49) | TACR1CCR5TACR2 | |
| SCHEMBL297293 | 0.77 | TACR3 (0.48) | TACR1CCR5TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | EPHX2 3856/4885P2RX7 146/4885CCR2 751/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | EPHX2 3856/4885P2RX7 146/4885CCR2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.